- Home
- ILMN
ILMN
Illumina Inc.
as 07-26-2024 4:00pm EST
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 17.0B | IPO Year: | 2000 |
| Target Price: | $159.39 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $86.58 - $190.31 | Next Earning Date: | 08-06-2024 |
| Revenue: | $4,493,000,000 | Revenue Growth: | 1.03% |
| Revenue Growth (this year): | 2.15% | Revenue Growth (next year): | 7.09% |
Stock Insider Trading Activity of Illumina Inc. (ILMN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thaysen Jacob | ILMN | Chief Executive Officer | Feb 22 '24 | Buy | $134.91 | 5,085 | $686,017.35 | 12,616 | SEC Form 4 |
| Thaysen Jacob | ILMN | Chief Executive Officer | Feb 22 '24 | Buy | $135.69 | 1,553 | $210,726.57 | 14,169 | SEC Form 4 |
| Thaysen Jacob | ILMN | Chief Executive Officer | Feb 22 '24 | Buy | $137.18 | 692 | $94,928.56 | 14,861 | SEC Form 4 |
Latest Illumina Inc. News
ILMN Breaking Stock News: Dive into ILMN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Insider Monkey
2 days ago
Here’s Why You Should Add Illumina (ILMN) to Your Portfolio
Zacks
4 days ago
Why Illumina (ILMN) Could Beat Earnings Estimates Again
Zacks
4 days ago
Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet
Zacks
4 days ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Insider Monkey
8 days ago
Should You Consider Adding Illumina (ILMN) to Your Portfolio?
PR Newswire
8 days ago
Illumina to Present Upcoming Strategy Update
Argus Research
8 days ago
Analyst Report: Illumina Inc
Compare ILMN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ILMN Illumina Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.